ABC06: ASC alone or with mFOLFOX for advanced biliary tract cancer

• Research type

  Research Study

• Full title

  A Phase III, randomised, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy for patients with locally advanced/metastatic biliary tract cancers previously treated with cisplatin / gemcitabine chemotherapy

• IRAS ID

  128871

• Contact name

  Juan Valle

• Contact email

  juan.valle@christie-tr.nwest.nhs.uk

• Sponsor organisation

  The Christie NHS Foundation Trust

• Eudract number

  2013-001812-30

• Clinicaltrials.gov Identifier

  NCT01926236

• Research summary

  The purpose of this study is to determine whether fit patients (with ECOG performance score of 0-1) with advanced biliary tract cancer (ABC) benefit from chemotherapy in the second-line setting (after prior therapy with cisplatin and gemcitabine) in terms of overall survival.

• REC name

  North West - Haydock Research Ethics Committee

• REC reference

  13/NW/0702

• Date of REC Opinion

  16 Oct 2013

• REC opinion

  Favourable Opinion